<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985539</url>
  </required_header>
  <id_info>
    <org_study_id>NL72631.091.20</org_study_id>
    <nct_id>NCT04985539</nct_id>
  </id_info>
  <brief_title>The Personalized Parkinson Project de Novo Cohort</brief_title>
  <acronym>PPP-novo</acronym>
  <official_title>The Personalized Parkinson Project de Novo Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Verily Life Sciences LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, the Movement Disorders Society (MDS)-UPDRS scale remains the gold standard to&#xD;
      document the outcomes in clinical trials for Parkinson's disease (PD). The MDS-UPDRS is far&#xD;
      from infallible, as it is based on subjective scoring (using a rather crude ordinal score),&#xD;
      while execution of the tests depends on clinical experience. Not surprisingly, the scale is&#xD;
      subject to both significant intra- and inter-rater variability that are sufficiently large to&#xD;
      mask an underlying true difference between an effective intervention and placebo. Digital&#xD;
      biomarkers may be able to overcome the limitations of the MDS-UPDRS, as they continuously&#xD;
      collects real-time data, during the patient's day to day activities. In this study the&#xD;
      investigators are interested in developing algorithms to track progression of bradykinesia,&#xD;
      gait impairment, postural sway, tremor, physical activity, sleep quality, and autonomic&#xD;
      dysfunction (the latter being derived from e.g. skin conductance and changes in heart rate&#xD;
      variability).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This PPP de NOVO cohort aims to validate novel digital biomarkers for disease progression,&#xD;
      fostering the unique research infrastructure and data collection protocol that are available.&#xD;
      The PPP de NOVO cohort consists of patients with de novo (i.e., newly diagnosed and&#xD;
      previously untreated) Parkinson's disease who will be followed longitudinally for two years.&#xD;
      De novo patients create the opportunity to study disease progression without interference of&#xD;
      pharmacological treatment. The observation of this natural process in the earliest course of&#xD;
      the disease is highly relevant for the development disease modifying interventions, which are&#xD;
      likely to have the biggest potential in the earliest phases of the disease, when the loss of&#xD;
      substantia nigra cells is minimal. In particular, the investigators will deploy the PPP de&#xD;
      NOVO cohort for the development of digital biomarkers that could serve as a surrogate or,&#xD;
      with time, possibly as key secondary or even a primary outcome in future clinical trials of&#xD;
      disease-modifying interventions. Digital biomarkers hold great promise in this regard, as&#xD;
      they provide a means to objectively track patients and measure their function in their own&#xD;
      living environment, unobtrusively, and over long periods of time. The outcomes are&#xD;
      potentially more sensitive than currently available clinical scales, which also be included&#xD;
      in the protocol and perhaps also more relevant as they provide an insight into daily life&#xD;
      functioning over extended periods of time.&#xD;
&#xD;
      The primary objective is to develop novel digital biomarkers that allow for measurement of&#xD;
      disease progression in de novo PD patients.&#xD;
&#xD;
      Our hypothesis is that digital progression biomarkers will have greater sensitivity and&#xD;
      greater power for detecting disease progression than conventional scales.&#xD;
&#xD;
      The secondary objective is to test the feasibility of the Proof-Of-Concept (POC) study&#xD;
      protocol that UCB Pharma will use for their potentially disease modifying treatment. The PPP&#xD;
      de NOVO study is considered instrumental in optimizing planning, data acquisition, analysis&#xD;
      and interpretation of the digital data collected in the POC study.&#xD;
&#xD;
      The third objective of this study is to create an extensive longitudinal dataset describing&#xD;
      the clinical and functional characteristics of a representative PD de novo cohort to allow&#xD;
      researchers to investigate important unanswered questions in PD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for gait</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) gait-related features extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for gait will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for tremor</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) tremor-related features extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for tremor will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for bradykinesia</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) bradykinesia-related features extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for bradykinesia will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for postural sway</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) postural sway-related features extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for postural sway will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for time active vs inactive during the day</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) features that reflect the time a person is active and inactive during the day, extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for time active vs inactive during the day will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for heart rate variability</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) features that reflect heart rate variability, extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for heart rate variability will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Annual change in digital biomarkers for skin impedance</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Identify (a combined set of) features that reflect skin impedance, extracted from wearable sensor data, that are relevant for patients and that are sensitive to disease progression in de novo PD patients. Which outcome and which Unit of Measure for skin impedance will be selected cannot be defined on forehand, as this is part of the analytical approach, as described by Manta et al. (Digital measures of health that matter to patients. Digit Biomark 2020;4:69-77).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived feasibility of longitudinal follow-up and repeated assessments</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Participants will be asked to complete an exit survey, which asks for their perception of the protocol burden (0-10 point scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to weekly structured tasks</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Percentage of weeks in which the tasks were completed during the two-year follow-up (0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to wearing the smartwatch</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Percentage of weartime during the two-year follow-up (0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drop-out rate</measure>
    <time_frame>From baseline till two year follow-up</time_frame>
    <description>Percentage of participants who withdraw their informed consent during the two-year follow-up (0-100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PRO-Mobility</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Participants will be asked to complete a 23-items Patient Reported Outcome (PRO) survey on mobility-related aspects, on a 0-4 scale. Total score ranges from 0-72.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGI-S Mobility</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Patient Global Impression of Severity (PGI-S): participants will be asked to score their perceived severity of their mobility problems over the past 7 days on a 4-point scale (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PRO-Fatigue</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Participants will be asked to complete a 31-items Patient Reported Outcome (PRO) survey on fatigue-related aspects, on a 0-4 scale. Total score ranges from 0-124.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGI-S Fatigue</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Patient Global Impression of Severity (PGI-S): participants will be asked to score their perceived severity level of fatigue over the past 7 days on a 4-point scale (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PRO-Functional Slowness</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Participants will be asked to complete a 44-items Patient Reported Outcome (PRO) survey on functional slowness-related aspects, on a 0-4 scale. Total score ranges from 0-176.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGI-S Functional Slowness</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Patient Global Impression of Severity (PGI-S): participants will be asked to score their perceived severity level of functional slowness over the past 7 days on a 4-point scale (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGI-S Symptoms</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Patient Global Impression of Severity (PGI-S): participants will be asked to score their perceived severity of their Parkinson's disease symptoms over the past 7 days on a 4-point scale (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PGI-C Symptoms</measure>
    <time_frame>From baseline till two year follow-up, every 13 weeks</time_frame>
    <description>Patient Global Impression of Change(PGI-S): participants will be asked to score their perceived change in severity of their Parkinson's disease symptoms since baseline on a 4-point scale (none, mild, moderate, severe)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinsonian Disorders</condition>
  <condition>Basal Ganglia Diseases</condition>
  <condition>Brain Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Movement Disorders</condition>
  <condition>Neurodegenerative Diseases</condition>
  <arm_group>
    <arm_group_label>PD de novo</arm_group_label>
    <description>Observational.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Verily Study Watch</intervention_name>
    <description>Participants wear the Verily Study Watch for 2 years, for longitudinal data collection.</description>
    <arm_group_label>PD de novo</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood specimen from all enrolled patients.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any adult with Parkinson's disease who meets the inclusion criteria and does not meet the&#xD;
        exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has Parkinson's disease of â‰¤2 years of duration, defined as the time since the&#xD;
             diagnosis was made by a neurologist.&#xD;
&#xD;
          -  Subject is an adult, at least 18 years of age.&#xD;
&#xD;
          -  Subject can read and understand Dutch.&#xD;
&#xD;
          -  Subject has completed the IRB-approved Informed Consent.&#xD;
&#xD;
          -  Subject is willing, competent, and able to comply with all aspects of the protocol,&#xD;
             including follow-up schedule and bio-specimen collection.&#xD;
&#xD;
          -  Subject has never been treated before with any symptomatic dopaminergic drug treatment&#xD;
             for Parkinson's disease and is not expected to start treatment for motor symptoms of&#xD;
             PD within 52 weeks from baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has co-morbidities that would hamper interpretation of parkinsonian&#xD;
             disability, such as coincident musculoskeletal abnormalities, in the opinion of the&#xD;
             Investigator.&#xD;
&#xD;
          -  Subject is taking Mucuna Pruriens.&#xD;
&#xD;
          -  For Study Watch: subject is allergic to nickel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastiaan R Bloem, MD, PhD, RFCPE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marjan Meinders, PhD</last_name>
    <phone>+31243613450</phone>
    <email>Marjan.Meinders@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tessa van de Zande, MSc</last_name>
    <phone>+31243613450</phone>
    <email>tessa.vandezande@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan Meinders, PhD</last_name>
      <phone>+31243613450</phone>
      <email>info@parkinsonopmaat.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Wearable sensors</keyword>
  <keyword>Disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
    <mesh_term>Basal Ganglia Diseases</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The dataset generated in this study will become available to qualified researchers worldwide, provided research questions are approved by the Research and Data Sharing Review Committee (RDSRC). The RDSRC will protect subjects' privacy by limiting the availability of the study data and controlling access to sources of information that might potentially be used to identify the individual subjects associated with the bio-specimen analysis.&#xD;
The RDSRC will assess the relevance and scientific quality of research proposals for which study data or material is requested. These responsibilities include the consideration of applications for:&#xD;
access to the resources obtained in this study, including data or biomaterials&#xD;
applications for endorsement of a scientific project using study materials;&#xD;
applications for endorsement of a clinical study using study materials.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Not decided yet.</ipd_time_frame>
    <ipd_access_criteria>Currently no list of criteria is available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

